| Website | www.mgshell.com |
| Field (and ATECO code) | Design, development, production, characterization and commercialization of biomedical devices – 72.10.29. |
| Target market | Biomedical, Pharmaceutical, Drug Delivery, Ophthalmology, Applied Research |
| Year of incorporation | 2019 |
Activities
MgShell is an Italian company developing innovative drug delivery technologies for the treatment of ocular diseases. Its platform, based on magnesium carriers for the controlled and sustained release of drugs, aims to improve therapeutic efficacy and patient adherence while reducing treatment burden and healthcare costs. Currently undergoing preclinical validation, the technology is primarily intended for ophthalmic applications, with potential extension to non-ophthalmic fields as well.
Founders
Discover the founders of MgShell
CEO of MgShell, he earned a PhD from the Department of Chemistry, Materials and Chemical Engineering at Politecnico di Milano, focusing on the design and development of magnesium-based drug delivery systems.
CTO of MgShell, he earned a PhD from the Department of Chemistry, Materials and Chemical Engineering at Politecnico di Milano, focusing on the development and characterization of medical devices for cardiovascular applications.